ST-2427

ST-2427 is an experimental, intravenous, non-opioid analgesic developed for the management of moderate-to-severe pain. It is a highly selective small molecule inhibitor of the voltage-gated sodium channel NaV1.7 (sodium channel protein type IX alpha subunit), which is predominantly expressed in peripheral nerve fibers and plays a critical role in pain signal transmission. By selectively blocking NaV1.7, ST-2427 aims to prevent electrical signals responsible for pain from reaching the central nervous system, offering potential advantages over opioid therapies by reducing risks of addiction and CNS side effects. The drug was developed by SiteOne Therapeutics with origins at Stanford University and reached Phase 1 clinical trials for acute and postoperative pain before development was terminated[1][2][3][4][5][7].